A Repeated Dose Study of the Metabolism and Action Evaluation of OROS Hydromorphone HCI (Slow Release) Tablets in Patients With Chronic Pain

NCT00410878 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Pain
Analgesics, Opioid

Interventions

DRUG: OROS Hydromorphone HCI (slow release)

Sponsor

Alza Corporation, DE, USA